INNOVA CAPTAB Financial Statement Analysis
|
||
|
The Revenues of INNOVA CAPTAB have increased by 16.72% YoY .
The Earnings Per Share (EPS) of INNOVA CAPTAB has increased by 16.45 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
INNOVA CAPTAB Last 5 Annual Financial Results
[BOM: 544067|NSE : INNOVACAP]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,081 Cr | ₹926 Cr | ₹801 Cr | ₹411 Cr | ₹373 Cr |
| Expenses | ₹927 Cr | ₹813 Cr | ₹705 Cr | ₹356 Cr | ₹322 Cr |
| Operating Profit (Excl OI) | ₹154 Cr | ₹114 Cr | ₹96 Cr | ₹54 Cr | ₹51 Cr |
| Other Income | ₹12 Cr | ₹9.20 Cr | ₹2.88 Cr | ₹1.37 Cr | ₹1.30 Cr |
| Interest | ₹21 Cr | ₹20 Cr | ₹5.68 Cr | ₹3.93 Cr | ₹4.63 Cr |
| Depreciation | ₹16 Cr | ₹11 Cr | ₹7.50 Cr | ₹5.59 Cr | ₹10 Cr |
| Profit Before Tax | ₹130 Cr | ₹92 Cr | ₹86 Cr | ₹46 Cr | ₹38 Cr |
| Profit After Tax | ₹94 Cr | ₹68 Cr | ₹64 Cr | ₹35 Cr | ₹28 Cr |
| Consolidated Net Profit | ₹94 Cr | ₹68 Cr | ₹64 Cr | ₹34 Cr | ₹28 Cr |
| Earnings Per Share (Rs) | ₹16.49 | ₹14.16 | ₹531.54 | ₹286.86 | ₹232.23 |
| PAT Margin (%) | 8.71 | 7.23 | 7.91 | 8.38 | 7.46 |
| ROE(%) | 17.04 | 28.02 | 36.19 | 27.04 | 28.92 |
| ROCE(%) | 19.06 | 24.34 | 30.64 | 28.42 | 26.48 |
| Total Debt/Equity(x) | 0.29 | 0.85 | 0.95 | 0.31 | 0.48 |
Key Financials |
||
| Market Cap | : | ₹ 5,200.1 Cr |
| Revenue (TTM) | : | ₹ 1,243.7 Cr |
| Net Profit(TTM) | : | ₹ 128.3 Cr |
| EPS (TTM) | : | ₹ 22.4 |
| P/E (TTM) | : | 40.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INNOVA CAPTAB | 2.5% | -1.9% | 92.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.3% | -2.9% | 11.5% |
| DIVIS LABORATORIES | 0.7% | 7.4% | 48.1% |
| CIPLA | -0.1% | 0.2% | -2.1% |
| TORRENT PHARMACEUTICALS | 2.3% | -0.5% | 13.8% |
| DR REDDYS LABORATORIES | 3.2% | 10.3% | 11.7% |
| MANKIND PHARMA | 1.1% | -7% | 9.7% |
| ZYDUS LIFESCIENCES | 0.2% | 7.8% | -9.8% |
| LUPIN | 0.3% | -3.4% | 23.6% |
INNOVA CAPTAB Revenues
[BOM: 544067|NSE : INNOVACAP]
| Y-o-Y | 16.72 % |
| 5 Yr CAGR | 30.46 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,081 Cr | 16.72 | |
| Mar2023 | ₹926 Cr | 15.72 | |
| Mar2022 | ₹801 Cr | 94.94 | |
| Mar2021 | ₹411 Cr | 10.00 | |
| Mar2020 | ₹373 Cr | - | |
INNOVA CAPTAB Operating Profit
[BOM: 544067|NSE : INNOVACAP]
| Y-o-Y | 35.91 % |
| 5 Yr CAGR | 31.96 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹154 Cr | 35.91 | |
| Mar2023 | ₹114 Cr | 18.36 | |
| Mar2022 | ₹96 Cr | 76.23 | |
| Mar2021 | ₹54 Cr | 6.98 | |
| Mar2020 | ₹51 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 16.38 % |
| 5 Yr CAGR | 1.15 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 14.28% | 16.38 | |
| Mar2023 | 12.27% | 2.34 | |
| Mar2022 | 11.99% | -9.65 | |
| Mar2021 | 13.27% | -2.71 | |
| Mar2020 | 13.64% | - | |
INNOVA CAPTAB Profit After Tax
[BOM: 544067|NSE : INNOVACAP]
| Y-o-Y | 38.84 % |
| 5 Yr CAGR | 35.65 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹94 Cr | 38.84 | |
| Mar2023 | ₹68 Cr | 6.54 | |
| Mar2022 | ₹64 Cr | 85.30 | |
| Mar2021 | ₹34 Cr | 23.53 | |
| Mar2020 | ₹28 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 20.47 % |
| 5 Yr CAGR | 3.95 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 8.71 % | 20.47 | |
| Mar2023 | 7.23 % | -8.60 | |
| Mar2022 | 7.91 % | -5.61 | |
| Mar2021 | 8.38 % | 12.33 | |
| Mar2020 | 7.46 % | - | |
INNOVA CAPTAB Earnings Per Share (EPS)
[BOM: 544067|NSE : INNOVACAP]
| Y-o-Y | 16.45 % |
| 5 Yr CAGR | -48.38 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹16 | 16.45 | |
| Mar2023 | ₹14 | -97.34 | |
| Mar2022 | ₹532 | 85.30 | |
| Mar2021 | ₹287 | 23.52 | |
| Mar2020 | ₹232 | - | |
INNOVA CAPTAB Return on Capital Employed (ROCE)
[BOM: 544067|NSE : INNOVACAP]
| Y-o-Y | -21.69 % |
| 5 Yr CAGR | -7.89 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 19.06% | -21.69 | |
| Mar2023 | 24.34% | -20.56 | |
| Mar2022 | 30.64% | 7.81 | |
| Mar2021 | 28.42% | 7.33 | |
| Mar2020 | 26.48% | - | |
INNOVA CAPTAB Share Price vs Sensex
| Current Share Price | : | ₹909.1 |
| Current MarketCap | : | ₹ 5,200.1 Cr |
| Updated EOD on | : | Jun 13,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INNOVA CAPTAB | 2.5% |
-1.9% |
92.4% |
| SENSEX | -1.3% |
-0.3% |
5.8% |
INNOVA CAPTAB related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | 1.8% | 4.1% | 21.2% |
| BSE SMALLCAP | -0.1% | 6.8% | 9.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 0.7% | 6.3% | 12.1% |
| NIFTY TOTAL MARKET | -1.1% | 2% | 5.5% |
| NIFTY IPO INDEX | -1.1% | 3.4% | NA |
You may also like the below Video Courses
FAQ about INNOVA CAPTAB Financials
How the annual revenues of INNOVA CAPTAB have changed ?
The Revenues of INNOVA CAPTAB have increased by 16.72% YoY .
How the Earnings per Share (EPS) of INNOVA CAPTAB have changed?
The Earnings Per Share (EPS) of INNOVA CAPTAB has increased by 16.45 % YoY .
Check out Intrinsic Value of Peers of INNOVA CAPTAB
Compare Stock Analytics of Peers of INNOVA CAPTAB
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
